Atlas Trials

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

Clinical trial NCT02996448 · TERMINATED

Trial details

NCT number
NCT02996448
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Autosomal-dominant Hyper-IgE Syndrome
Start date
2016-11-17
Primary completion
2018-07-22
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.